As sequencing costs decrease and the clinical relevance of genetics increases, genomic data have now entered the everyday clinical practice of epilepsy management. Therefore, specialists should be able to interpret genetic data and use them to make decisions on the treatment of patients, argued Dr Guido Rubboli (University of Copenhagen, Denmark) .
Applying genetics may end the diagnostic Odyssey and provide useful prognostic information, Dr Rubboli said, but also help to improve treatment. It allows for choosing treatments that correct specific metabolic defects, to avoid adverse events that can aggravate the pathogenic defect, and to select anti-epileptic drugs (AEDs) that counteract the functional disturbance caused by a gene mutation. Mutations in SCN1A, SCN1B, SCN2A, SCN3A, SCN8A, and SCN9A are responsible for a considerable proportion of cases of drug-resistant epilepsies with childhood onset.
Most epilepsy genes produce a wide range of sei...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« White matter matters in Parkinson’s disease Next Article
Pegzilarginase highly effective in arginase-1 deficiency »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.